Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya Limited has announced the issuance of 25,000 ordinary shares following the exercise and conversion of vested employee incentive performance rights. This move reflects the company’s ongoing commitment to incentivize its workforce as it continues to advance its AI technology for coronary artery disease detection, potentially impacting its market positioning and stakeholder interests.
More about Artrya Limited
Artrya Limited is an applied artificial intelligence healthcare company based in Perth, Australia, founded in 2018 and listed on the Australian Securities Exchange in 2021. The company focuses on improving the diagnosis of coronary heart disease through its AI platform, which works alongside clinicians to provide a comprehensive overview of at-risk patients. Artrya is developing deep-learning algorithms aimed at predicting and preventing acute coronary events, pending regulatory approval in the US.
YTD Price Performance: 33.96%
Average Trading Volume: 196,865
Technical Sentiment Consensus Rating: Sell
For detailed information about AYA stock, go to TipRanks’ Stock Analysis page.